TRA was independently associated with a 35 % reduction in 30-day mortality risk ( odds ratio [ OR ] : 0.65 [ 95 % confidence interval ( CI ) : 0.59 to 0.72 ] ; p < 0.0001 ) , with the magnitude of mortality reduction related to baseline bleeding risk ( MMRS < 10 , OR : 0.73 [ 95 % CI : 0.62 to 0.86 ] ; MMRS 20 , OR : 0.53 [ 95 % CI : 0.47 to 0.61 ] ) .